Colin Macaulay
Founder at Viron Therapeutics, Inc.
Colin Macaulay active positions
| Companies | Position | Start | End |
|---|---|---|---|
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Chief Tech/Sci/R&D Officer | 1996-12-31 | - |
| Founder | 2009-10-12 | - |
Career history of Colin Macaulay
Training of Colin Macaulay
| University of Alberta | Doctorate Degree |
Statistics
International
| Canada | 3 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
- Stock Market
- Insiders
- Colin Macaulay
- Experience
